Uridine triacetate
 | |
| Clinical data | |
|---|---|
| Trade names | Vistogard, Xuriden |
| Other names | vistonuridine |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a616020 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Pyrimidine catabolic pathway |
| Onset of action | Tmax = 2–3 hours |
| Elimination half-life | 2–2.5 hours |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.021.710 |
| Chemical and physical data | |
| Formula | C15H18N2O9 |
| Molar mass | 370.314 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Uridine triacetate (INN),[1] formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine[2] used:
- in the treatment of hereditary orotic aciduria (brand name Xuriden /ˈzʊərədɛn/ ZOOR-ə-den);[3]
- to treat people following an overdose of chemotherapy drugs 5-fluorouracil (5-FU) or capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name Vistogard).[4][5][6][7][8]
Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics. It was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and approved for use in the United States in 2015.[9][10][11]
References
[edit]- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65" (PDF). World Health Organization. p. 92. Retrieved 12 March 2017.
- ^ "Uridine triacetate — DrugBank Page". 12 March 2017.
- ^ "Xuriden- uridine triacetate granule". DailyMed. 16 December 2019. Retrieved 20 October 2020.
- ^ "Vistogard- uridine triacetate granule". DailyMed. 15 November 2018. Retrieved 20 October 2020.
- ^ "BTG Announces FDA Approval of Vistogard (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine". BTG International Ltd. 11 December 2015. Retrieved 12 March 2017.
- ^ "Approved Drugs — Uridine Triacetate". U.S. Food and Drug Administration. Archived from the original on 3 March 2016. Retrieved 12 March 2017.
- ^ Cada DJ, Mbogu U, Bindler RJ, Baker DE (June 2016). "Uridine Triacetate". Hospital Pharmacy. 51 (6): 484–8. doi:10.1310/hpj5106-484. PMC 4911989. PMID 27354750.
- ^ Ison G, Beaver JA, McGuinn WD, Palmby TR, Dinin J, Charlab R, et al. (September 2016). "FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs". Clinical Cancer Research. 22 (18): 4545–4549. doi:10.1158/1078-0432.CCR-16-0638. PMID 27401247. S2CID 25746700.
- ^ "Xuriden (uridine triacetate) oral granules". U.S. Food and Drug Administration (FDA). 8 October 2015. Archived from the original on 8 December 2019. Retrieved 7 December 2019.
This article incorporates text from this source, which is in the public domain.
- ^ "Drug Trials Snapshots: Xuriden". U.S. Food and Drug Administration (FDA). 4 September 2015. Archived from the original on 8 December 2019. Retrieved 8 December 2019.
- ^ "Previous Cumulative CY CDER BT Approvals" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original on 8 December 2019. Retrieved 7 December 2019.
External links
[edit]- "Uridine triacetate". Drug Information Portal. U.S. National Library of Medicine.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |